Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis


Published in: International journal of antimicrobial agents

DOI: 10.1016/j.ijantimicag.2015.06.008

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2015

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis

J.A. Dijkstra a, R. van Altena b, O.W. Akkerman b, W.C.M. de Lange b, J.H. Proost c, T.S. van der Werf b, d, J.G.W. Kosterink a, c, J.W.C. Alffenaar a, e

a University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands
b University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands
c University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmacokinetics, Toxicology and Targeting, Groningen, The Netherlands
d University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands
e University of Groningen, Department of Pharmacy, Pharmacotherapy and Pharmaceutical Care, Groningen, The Netherlands

A R T I C L E   I N F O

Article history:
Received 10 February 2015
Accepted 1 June 2015

Keywords:
Amikacin
Kanamycin
Tuberculosis
Pharmacokinetics
Pharmacokinetic model
Limited sampling

A B S T R A C T

Amikacin and kanamycin are considered important and effective drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB). Unfortunately, the incidence of toxicity is high and is related to elevated drug exposure. In order to achieve a balance between efficacy and toxicity, a population pharmacokinetic (PPK) model may help to optimise drug exposure. Patients with MDR-TB who had received amikacin or kanamycin as part of their treatment and who had routinely received therapeutic drug monitoring were evaluated. A PPK model was developed and subsequently validated. Using this model, a limited sampling model was developed. Eleven patients receiving amikacin and nine patients receiving kanamycin were included in this study. The median observed 24-h area under the concentration–time curve (AUC0–24h) was 77.2 mg h/L [interquartile range (IQR) 64.7–96.2 mg h/L] for amikacin and 64.1 mg h/L (IQR 55.6–92.1 mg h/L) for kanamycin. The PPK model was developed and validated using n–1 cross-validation. A robust population model was developed that is suitable for predicting the AUC0–24h of amikacin and kanamycin. This model, in combination with the limited sampling strategy developed, can be used in daily routine to guide dosing but also to assess AUC0–24h in phase 3 studies.

1. Introduction

Tuberculosis (TB) is a life-threatening disease. Approximately 1.4 million people die as a consequence of this disease every year [1]. Multidrug-resistant TB (MDR-TB) is caused by strains of Mycobacterium tuberculosis that are resistant to at least rifampicin and isoniazid. In 2011 an estimated 310 000 of all newly reported TB cases were MDR-TB [1], and in the most recent World Health Organization (WHO) report on TB the incidence of MDR-TB was estimated at ca. 480 000 [2]. Treatment success is associated with a prolonged duration of therapy of a minimum of 18 months with second-line drugs [3].

Amikacin and kanamycin are classified as group 2 (injectable agents) for the treatment of MDR-TB [4]. Recommended dosages are 15–20 mg/kg with a maximum of 1000 mg daily for both amikacin and kanamycin [4]. The reported minimum inhibitory concentrations (MICs) of amikacin and kanamycin are 0.5–1 mg/L and 1–2 mg/L, respectively [5].

The pharmacodynamic (PD) index of aminoglycosides is usually quantified as the ratio of the maximum blood concentration (Cmax) to the MIC. Aminoglycoside dosing regimens with multiple doses per day were designed to reach certain Cmax levels, whilst minimising trough blood concentration (Cmin) levels was required to avoid toxicity. However, in order to detect interindividual and intrindivid-ual differences in clearance or volume of distribution, the area under the concentration–time curve (AUC) might be a more sensitive pharmacokinetic parameter in comparison with the Cmax or Cmin [6].
Interindividual variation in pharmacokinetics may contribute to toxicity and efficacy. Zhu et al. reported that the AUC of streptomycin in 19 patients varied from 124 μg·h/ml to 680 μg·h/ml, whilst the Cmax varied from 9 μg/ml to 107 μg/ml [7]. Interindividual variation in Cmax was also observed for amikacin (median 46 mg/L, range 26–54 mg/L) and kanamycin (median 44 mg/L, range 33–65 mg/L) [8]. This urges the need for a pharmacokinetic model to assess interindividual variability.

Side effects of aminoglycosides are ototoxicity and nephrotoxicity. The prevalence of ototoxicity varies from 18% [9] to 37% [8] and that of nephrotoxicity from 7.5% [9] to 15% [8]. Treatment duration and the cumulative dose were correlated with these side effects, but not the dose or the dosing frequency [8–10]. In addition to the cumulative dose, the cumulative 24-h AUC (AUC0–24h) is also related both to nephrotoxicity and ototoxicity [11–13]. A retrospective evaluation of a Dutch cohort showed that a MDR-TB treatment regimen including aminoglycoside drug concentration-guided dosing resulted in high effectiveness with excellent treatment outcome, without severe adverse drug reactions [14]. During the study period, no treatment failures or documented relapses were observed using a relatively low dose of aminoglycosides in an analysis of all MDR-TB patients diagnosed and treated in The Netherlands [14]. A population pharmacokinetic (PPK) model makes it possible to prospectively acquire pharmacokinetic data of aminoglycosides in the treatment of TB in order to design new optimised regimens in the treatment of MDR-TB.

As collecting full blood plasma curves of amikacin or kanamycin to estimate the AUC0–24h and clearance is expensive and burdensome for patients, a limited sampling strategy to perform therapeutic drug monitoring (TDM) will help to improve pharmacotherapy and reduce costs [15]. The objective of this study was to develop a PPK model of amikacin and kanamycin to assess both the AUC0–24h and Cmax based on retrospective data. This model could be used in a prospective study to evaluate both toxicity and efficacy. Furthermore, a limited sampling strategy will be designed using this pharmacokinetic model.

2. Materials and methods

2.1. Study population

All patients at the Tuberculosis Center Beatirixoord (University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) who were diagnosed with MDR-TB after 1 January 2000 and who met the inclusion criteria were included in this retrospective study. Inclusion criteria included age >18 years, treatment with amikacin or kanamycin for longer than 2 days, and availability of at least three plasma concentrations from one dose on the same day. Medical and demographic data were collected from the medical records. Demographic data included age, height and body weight at the start of treatment. Medical data included the aminoglycoside used, the administered dose and serum creatinine (SCR) at baseline. This study was evaluated by the local ethics committee and was allowed according to Dutch law owing to its retrospective nature. Drug susceptibility was determined using the Mycobacteria Growth Indicator Tube (MGIT™) method by the Tuberculosis Reference Laboratory of the National Institute for Public Health and the Environment (RIVM, The Netherlands).

2.2. Pharmacokinetics

Data on the plasma concentrations of the patients included were retrieved from the laboratory information system. Blood analyses were performed by a validated liquid chromatography mass spectrometry (LC–MS/MS) (amikacin and kanamycin) [16] or a validated AxSYM (amikacin) (Abbott, Chicago, IL) method. Both methods were validated on precision and accuracy according to the US Food and Drug Administration (FDA) guidelines [17]. All pharmacokinetic calculations were performed using MW-Pharm 3.81 (Mediware, Groningen, The Netherlands) [18]. Individual pharmacokinetic parameters, including AUC, half-life (t1/2), clearance (CL), volume of distribution (Vd) and the elimination rate constant (kel) were calculated using the KinFit module of MW-Pharm using one-compartment analysis.

For amikacin and kanamycin, a model was developed separately using MW-Pharm using a one-compartment model as described previously [19]. We were not able to evaluate the performance of a two-compartment model since there the number of samples at the elimination phase of the curve was insufficient. Differences in pharmacokinetic parameters between both aminoglycosides were analysed using Mann–Whitney U-test.

Furthermore, a final model was developed with the amikacin and kanamycin curves combined. The distribution of the parameters of the final model developed was assessed by histograms generated by MW-Pharm. Furthermore, the predicted concentrations were compared with the observed concentrations using residual plots. The influence of the covariates age, weight, height, sex, body surface area (BSA), lean body mass and creatinine clearance (ClCr) on the renal elimination constant (kel) and Vd were tested for significance using MW-Pharm. The population parameters of the final model and their 95% confidence intervals (Cls) were calculated using a bootstrap method (n = 1000).

The elimination constant was calculated by the following formula: kel = kelim (metabolic elimination rate constant) (fixed to 0) + kel (renal elimination rate constant) * ClCr (creatinine clearance in ml/min/1.73 m²). The free fraction was estimated at 0.04 ± 0.08. The fat distribution was estimated at 0.4. Assay errors were set to 0.1 + 0.035 * [measured concentration], which captured the variation of both methods.

2.3. Limited sampling strategies

A PPK model was developed using the KinPop module of MW-Pharm. This module uses an iterative two-stage Bayesian population procedure [20]. The pharmacokinetic parameters were assumed to be log-normally distributed. The kel and Vd used to calculate the limited sampling strategies was calculated by the pharmacokinetic model.

Using Monte Carlo simulations, plasma concentrations at eight points in 8 h were calculated for 1000 virtual patients. Only models to optimise AUC were developed. Only practical sampling strategies were evaluated with a minimum time span between two sampling points of 1 h with a maximum of 8 h after administration. Only strategies with a root-mean-squared error (RMSE) of 11% were considered. The ability of the limited sampling model to predict the Cmax was assessed by entering both the concentrations at 1 h and 4 h combined into the model. The difference between the model-predicted Cmax and the limited sampling-predicted Cmax was calculated.

2.4. Statistics

All statistics were performed using IBM SPSS Statistics for Windows v.22.0 (IBM Corp., Armonk, NY). Validation of the pharmacokinetic model developed was performed by calculating new pharmacokinetic models based on experimental data of subsequently n−1 patients, which was previously used successfully [21,22]. With this ‘n−1’ pharmacokinetic model, AUC0–24h of the excluded patient was calculated. The AUC0–24h calculated with the model was compared with the n−1 validation AUC with a Bland–Altman plot. Furthermore, all pharmacokinetic parameters
of the \( n-1 \) model, including the AUC\(_{0–24h} \) were compared with the PPK model using Wilcoxon signed-rank test. Differences in pharmacokinetic parameters between amikacin and kanamycin were assessed using Mann–Whitney U-test. In addition, correlations between demographic and pharmacokinetic data were tested for significance with Spearman correlation or in the case of categorical data with Mann–Whitney U-test.

3. Results

In total, 30 plasma concentration curves were retrieved from the medical dossiers of 20 patients. Sample times of the individual curves varied between individuals and curves, with a maximum time span of 24 h. Eleven patients had received amikacin 400 mg once daily, which resulted in 16 plasma concentration curves. In addition, 14 curves were retrieved from nine patients who had received kanamycin 400 mg once daily. The median body mass index (BMI) was 20.3 kg/m\(^2\) [interquartile range (IQR) 18.8–22.0 kg/m\(^2\)], with a median dose per kg body weight of 6.9 mg/kg (IQR 6.3–7.8 mg/kg). Demographic data are shown in Table 1.

The median AUC\(_{0–24h} \) of amikacin (400 mg) was 77.2 h mg/L (IQR 64.7–96.2 h mg/L). The median AUC\(_{0–24h} \) of kanamycin (400 mg) was slightly lower at 64.1 h mg/L (IQR 55.6–92.1 h mg/L). The coefficient of variation of the AUC\(_{0–24h} \) was 33%, indicating that the number of patients included in the model is sufficient to achieve a power level of >80% [23].

Population models of all amikacin and kanamycin curves at 400 mg were first built separately. The pharmacokinetic parameters of these models are displayed in Table 2. All parameters were compared using Mann–Whitney U-tests, however none of the parameter was significantly different between both models.

Therefore, we decided to pool the amikacin and kanamycin curves and to develop a new ‘combined’ model for both amikacin and kanamycin to include more variability in the model in order to increase the robustness of the model. A plot of the amikacin and kanamycin concentration time curves is shown in Fig. 1. The PPK parameters and corresponding 95% CIs are shown in Table 3. The estimated AUC\(_{0–24h} \) was 79.1 h mg/L (IQR 68.5–93.9 h mg/L) with a \( C_{\text{max}} \) of 26.6 mg/L (IQR 23.5–35.9 mg/L). This model was cross-validated using the proposed \( n-1 \) methodol-

### Table 1

Patients characteristics.*

<table>
<thead>
<tr>
<th></th>
<th>Amikacin group (n = 11)</th>
<th>Kanamycin group (n = 9)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex [n (%)]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>5 (45.5)</td>
<td>4 (44.4)</td>
<td>0.66*</td>
</tr>
<tr>
<td>Female</td>
<td>6 (54.5)</td>
<td>5 (55.6)</td>
<td></td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.75 (1.68–1.85)</td>
<td>1.62 (1.55–1.69)</td>
<td>0.02</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>60.0 (57.0–70.4)</td>
<td>51.0 (46.3–58.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Age (years)</td>
<td>26 (24–43)</td>
<td>31 (24.5–36.5)</td>
<td>0.75</td>
</tr>
<tr>
<td>Dose/kg body</td>
<td>6.67 (5.68–7.02)</td>
<td>7.85 (6.86–8.64)</td>
<td>0.02</td>
</tr>
<tr>
<td>weight (mg/kg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>20.2 (19.6–21.4)</td>
<td>20.5 (16.7–23.6)</td>
<td>0.82</td>
</tr>
<tr>
<td>SCR ((\mu)mol/L)</td>
<td>64.0 (52.0–68.0)</td>
<td>59.5 (46.5–70.5)</td>
<td>0.88</td>
</tr>
</tbody>
</table>

* BMI, body mass index; SCR, serum creatinine.

* Data are median (interquartile range) except for sex.

* Fisher’s exact test.

* Mann–Whitney U-test.

### Table 2

Pharmacokinetic parameters of the population model.

<table>
<thead>
<tr>
<th></th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amikacin model (n = 16)</td>
</tr>
<tr>
<td>CL (L/h)</td>
<td>4.62 (4.05–5.35)</td>
</tr>
<tr>
<td>( V_d ) (L)</td>
<td>12.0 (9.14–15.3)</td>
</tr>
<tr>
<td>AUC(_{0–24h} ) (h mg/L)</td>
<td>86.7 (75.1–99.0)</td>
</tr>
<tr>
<td>( C_{\text{max}} ) (mg/L)</td>
<td>26.2 (22.7–34.4)</td>
</tr>
</tbody>
</table>

IQR, interquartile range; CL, clearance; \( V_d \), volume of distribution; AUC\(_{0–24h} \), 24-h area under the concentration–time curve; \( C_{\text{max}} \), maximum serum concentration.

* Two-tailed exact Mann–Whitney U-test.

![Fig. 1. Plot of all amikacin and kanamycin curves (median ± standard error).](image-url)
The RMSE in predicting the $AUC_{0–24h}$, $t_{1/2}$, $V_d$, CL and $C_{max}$ was 0.36 h mg/L, 0.004 h, 0.041 L/h and 0.03 mg/L, respectively. A Bland–Altman plot concerning the $AUC_{0–24h}$ prediction is displayed in Fig. 2. One outlier was observed, with a deviation of ca. 2 h mg/L in the $AUC_{0–24h}$.

The influence of the covariates age, weight, height, sex, BSA, lean body mass and CLCr on $k_{el}$ and $V_d$ was tested for significance with MW\slash Pharm. Height ($P = 0.0046$) and CLCr ($P = 0.009$) correlated with $k_{el}$. In addition, sex ($P = 0.037$) correlated with $V_d$.

The $AUC_{0–24h}$, CL, $t_{1/2}$, $C_{max}$, time to the corresponding $C_{max}$ ($T_{max}$) and $V_d$ resulting from the $n$–1 validation were compared with all curves fitted to the PPK model; all parameters showed no difference ($AUC$, $P = 0.363$; CL, $P = 0.414$; $t_{1/2}$, $P = 0.317$; $C_{max}$, $P = 0.490$; $T_{max}$, $P = 1.000$; and $V_d$, $P = 0.472$).

The $V_d$ per kg body weight was higher in men than in women (median 0.24 L/kg vs. 0.19 L/kg; $P = 0.022$, Mann–Whitney U-test). The $C_{max}$ was higher in women (median 29.2 mg/L in women vs. 23.3 mg/L in men; $P = 0.012$, Mann–Whitney U-test); however, the $AUC_{0–24h}$ was not significantly different [median 78.3 h mg/L (95% CI 63.3–89.0 h mg/L) in men vs. 86.7 h mg/L (95% CI 71.4–111.7 h mg/L) in women; $P = 0.285$, Mann–Whitney U-test]. Furthermore, $V_d$, $t_{1/2}$ and $C_{max}$ correlated with the patients’ body weight and height (Spearman correlations, two-tailed test of significance). The $AUC_{0–24h}$ was correlated with the $C_{max}$ computed by the model: $AUC_{0–24h} = 1.636 \times C_{max} + 36.190$ with a correlation coefficient ($r$) of 0.61 using simple linear regression.

Based on the ‘combined’ population kinetic model, a limited sampling strategy was developed based on a patient with an average weight (59.9 kg), height (1.68 m) and SCr (63 μmol/L) and 35 years of age. Different limited sampling strategies were evaluated and subsequently the RMSE, bias and correlation coefficient of the $AUC$ were calculated. These different limited sampling strategies are displayed in Table 4. The $AUC$ is the most important parameter, since this indicates the precision in the prediction of the $AUC_{0–24h}$. Sampling at 1 h and 4 h after the start of the infusion resulted in a $AUC$ of 2.5% with a prediction bias of $–0.04\%$, respectively. The $C_{max}$ calculated by the model was compared with the $C_{max}$ calculated by the model based only on the concentrations at 1 h and 4 h. The median difference was $–0.04\%$ (IQR $–0.28\%$ to $0.38\%$).

Table 3

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean (95% CI)</th>
<th>S.D. (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$k_{el}$</td>
<td>0.00384 (0.00341–0.00432)</td>
<td>0.00143 (0.00113–0.00167)</td>
</tr>
<tr>
<td>$V_d$ corrected</td>
<td>0.2073 (0.1878–0.2284)</td>
<td>0.0664 (0.0456–0.0858)</td>
</tr>
</tbody>
</table>

CI, confidence interval; S.D., standard deviation; $k_{el}$, renal elimination constant; $V_d$, volume of distribution.

Table 4

<table>
<thead>
<tr>
<th>Time point(s) of sampling post-dose</th>
<th>$r$</th>
<th>Prediction bias (%)</th>
<th>RMSE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 h</td>
<td>0.984</td>
<td>$–3.02$</td>
<td>8.6</td>
</tr>
<tr>
<td>3 h</td>
<td>0.975</td>
<td>$–0.96$</td>
<td>10.2</td>
</tr>
<tr>
<td>4 h</td>
<td>0.944</td>
<td>0.63</td>
<td>14.9</td>
</tr>
<tr>
<td>1 h and 4 h</td>
<td>0.998</td>
<td>$–0.04$</td>
<td>2.5</td>
</tr>
<tr>
<td>1 h and 5 h</td>
<td>0.997</td>
<td>0.03</td>
<td>3.2</td>
</tr>
<tr>
<td>1 h and 3 h</td>
<td>0.997</td>
<td>$–0.4$</td>
<td>3.3</td>
</tr>
<tr>
<td>2 h and 4 h</td>
<td>0.996</td>
<td>$–0.24$</td>
<td>3.8</td>
</tr>
<tr>
<td>1 h and 6 h</td>
<td>0.996</td>
<td>0.27</td>
<td>4.1</td>
</tr>
<tr>
<td>1, 4 and 5 h</td>
<td>0.999</td>
<td>$–0.09$</td>
<td>1.7</td>
</tr>
<tr>
<td>1, 4 and 6 h</td>
<td>0.999</td>
<td>$–0.09$</td>
<td>1.8</td>
</tr>
<tr>
<td>1, 3 and 5 h</td>
<td>0.999</td>
<td>$–0.19$</td>
<td>1.8</td>
</tr>
<tr>
<td>1, 3 and 6 h</td>
<td>0.999</td>
<td>$–0.19$</td>
<td>1.8</td>
</tr>
<tr>
<td>1, 2 and 5 h</td>
<td>0.999</td>
<td>$–0.26$</td>
<td>1.8</td>
</tr>
</tbody>
</table>

RMSE, root-mean-squared error.

4. Discussion

We developed the first limited sampling strategy of amikacin and kanamycin in patients with TB. The $AUC$ found in predicting the $AUC_{0–24h}$, from samples at 1 h and 4 h is very low (2.5%). The model was successfully validated using the proposed $n$–1 cross-validation methodology. Since none of the relevant pharmacokinetic parameters showed a significant difference between amikacin and kanamycin, the final pharmacokinetic model was identical for both drugs. This model was considered appropriate for the assessment of individual pharmacokinetics during daily patient
care. Furthermore, this limited sampling model could be used to assess drug exposure in randomised controlled trials evaluating the efficacy of new regimens in the treatment of TB.

The pharmacokinetic parameters of the population model are higher than those in neutropenic patients (CL, 5.07 L/h vs. 4.43 L/h; V_d, 11.9 L vs. 8.92 L) [24]. This could be due to the use of a two-compartment model, whereas we used a one-compartment model. The authors found that the one-compartment model was unable to fit peaks and 12–24 h trough levels [24]. However, our model did not seem to have this disadvantage. We evaluated two-compartment models that provided a slightly better fit to our data, however these models provided unrealistic curves between 12 h and 24 h post-dose. A one-compartment model did not seem to have this disadvantage.

The V_d per kg body weight of critically ill patients is higher (0.39–0.45 L/kg vs. 0.20 L/kg in this study) [25]. However, these critically ill patients were experiencing sepsis or septic shock and gained volume during the first hours of resuscitation, explaining the higher V_d. A study with healthy volunteers showed that the pharmacokinetic parameters of amikacin are comparable with our population, except for clearance, which is slightly lower in our population (V_d, 11.0–11.15 L vs. 11.9 L; CL, 6.8–7.6 L/h vs. 5.07 L/h, depending on the amikacin dose of 7.5 mg/kg or 15.0 mg/kg) [26]. This difference in clearance might be caused by the nephrotoxic potential of these aminoglycosides during an extended period of time or the simultaneous administration of other antibiotics in the treatment of TB. Owing to the differences in population pharmacokinetics, it may be necessary to re-evaluate the proposed limited sampling strategy in other populations.

The V_d and C_max appeared to be significantly different between sexes. As women commonly have a higher percentage of body fat in comparison with men and aminoglycosides are very hydrophilic, this is an understandable correlation. In addition, the height and weight of women is generally lower than in men, which also affects the C_max and V_d. When targeting a certain C_max level, this would result in lower dosages for women, whilst the AUC_0–24h was not significantly different between both sexes.

Using the AUC/MIC ratio instead of the C_max/MIC ratio to monitor efficacy needs to be validated in an in vitro model for infection [27] and subsequently tested in a prospective clinical trial. Nevertheless, evidence in animal models suggests that the AUC_0–24h/MIC ratio predicts the efficacy of aminoglycoside therapy [28], and we speculate that this ratio can also be applied to humans [29]. However, this needs to be confirmed in a hollow-fibre model as has already been done for moxifloxacin [27].

In our TB centre, drug concentration-guided dosing of aminoglycosides is daily routine. The average dose given is 6.7 mg/kg, which is lower than the dose recommended by the WHO of 15–20 mg/kg [4]. Within our centre, aminoglycoside dose is based on individualised treatment based on the C_max/MIC ratio [30,31]. A retrospective study was performed to evaluate the treatment outcome with a treatment regimen incorporating this lower TDM-guided dosing and showed favourable results [14]. It should, however, be noted that an additional prospective study is necessary to confirm the efficacy of this relatively low dosage.

Although common practice, estimating the AUC_0–24h, with only a peak-level measurement (C_max) appears to be unreliable, with a correlation coefficient of only 0.61. The addition of a trough level at 24 h post-dose did not improve this estimation. However, measuring at 1 h and 4 h post-dose resulted in a high correlation of >0.99 and a low RMSE and bias. In addition, a fair estimation of the AUC_0–24h could be based on a one-point estimate 3 h post-dose.

Oral drugs used in the treatment of MDR-TB show strong correlations between the AUC_0–24h and the serum concentration 6 h post-dose [32]. The AUC_0–24h of aminoglycosides can be easily predicted with the sample times used to assess the exposure of oral drugs. With this strategy, estimation of the AUC_0–24h of several anti-TB drugs with only two or three samples is possible.

Fluoroquinolones and aminoglycosides are the cornerstone of MDR-TB treatment, however resistance development and toxicity are causes for concern. Treatment with fluoroquinolones, such as moxifloxacin, can be optimised using PK/PD modelling [22]. With this work we have shown that the assessment of aminoglycoside exposure using a limited sampling strategy is accurate. This limited sampling strategy provides a good estimation of the AUC_0–24h and is therefore suitable for use in outpatient clinics, but also during TDM in prospective clinical trials.

5. Conclusions

This study showed that the AUC_0–24h of amikacin and kanamycin can be predicted using a limited sampling strategy in combination with the developed PPK model. This strategy can be used to optimise TB treatment by reducing toxicity while maintaining efficacy but may also be included in phase 3 studies to collect data on drug exposure.

Funding: None.

Competing interests: None declared.

Ethical approval: This study was evaluated by the local ethics committee [IRB 2013–492] and was allowed according to Dutch law owing to its retrospective nature.

References


